The microchip technology is being licensed from Proteus Biomedical of Redwood City, California. Once activated by stomach acid, the embedded microchip begins sensing its environment and broadcasting data to a receiver worn by the patient. This receiver is also a transmitter that can send the data over the internet to a doctor.
The idea behind all this is to create “smart pills” that can sense what’s happening in the body and deliver that information to the patient’s doctor. Novartis plans to start microchipping its organ transplant anti-rejection drugs and then potentially expand microchipping to other pharmaceuticals in its product lineup. This same technology could soon end up in pills made by other drug companies, too.